Project Grant R44CA287485
Award Date
9/19/24
Completion Date
8/31/27
Dollars Obligated
$792K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $531,550 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Texas State University to conduct research on discovering novel druggable targets for neuroblastoma differentiation therapy. The research aims to systematically investigate the human druggable genome to identify differentiation-blocking oncogenes in neuroblastoma cells, validate their functions, and evaluate differentiation-inducing activities of inhibitors...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,237,513 to The Washington University to develop a novel combination molecular radiotherapy approach for treating relapsed and refractory neuroblastoma, the most common extracranial solid cancer in children. The research aims to evaluate the efficacy and biological effects of two high linear energy transfer radiopharmaceuticals, 77Br-MBBG targeting the norepinephrine transporter and...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $131,300 to Middle Tennessee State University to develop a novel dual inhibitor for the treatment of MYCN-amplified neuroblastoma. The key objectives are to: Identify the genes regulated by the N-MYC oncogene and its cofactors WDR5 and G9A, and determine how combined inhibition of these cofactors impacts N-MYC-dependent transcription. Pursue the identification and screening of potential...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $695,205 Project Grant to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant supports early-phase clinical trials of 211At-meta-astatobenzylguanidine (211At-MABG) for the treatment of neuroblastoma in children and advanced neuroendocrine cancers in adults. The researchers aim to assess the safety and...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop high-quality chemical probes to functionally annotate the epigenetic effector "reader" domains within the Bromodomain PHD Finger Transcription Factor (BPTF) in neuroblastoma, an aggressive pediatric cancer. The $738,024 award, effective from January 1, 2025 to December 31, 2029, aims to optimize BPTF bromodomain and plant homeodomain (PHD)...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine, a private non-profit university in Houston, Texas. The grant, titled "MYCN Drives a Suppressive Tumor Immune Microenvironment in Neuroblastoma," will fund research to investigate how the MYCN oncogene reprograms T cell metabolism to create an immune-suppressive tumor microenvironment in high-risk neuroblastoma. The goal is to delineate the...